Altium Capital Management’s 89bio ETNB Stock Holding History

Altium Capital Management’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-148,000	Closed	-$1.93M	–	130
2021 Q4	$1.93M	Buy	+148,000	New	+$2.34M	0.53%	70

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return

Altium Capital Management's ETNB Position: Q1 2022 in Review

Altium Capital Management sold out of 89bio (ETNB) in Q1 2022, closing a stake of 148,000 shares — an estimated $1.93M sold.

Altium Capital Management first reported a position in ETNB in Q4 2021 and held it in 1 quarter. The position peaked at $1.93M in Q4 2021. 69 funds tracked by Wall St. Rank hold ETNB as of Q1 2022.

Altium Capital Management reported no remaining 89bio position as of Q1 2022 after selling out during the quarter.
Altium Capital Management sold 148,000 89bio shares in Q1 2022, an estimated $1.93M.
Altium Capital Management first reported a position in 89bio in Q4 2021 and held it in 1 quarter.
Altium Capital Management's 89bio position peaked at $1.93M in Q4 2021.
69 funds tracked by Wall St. Rank held 89bio as of Q1 2022.

Based on Altium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.